![ΑΝΑΛΥΤΙΚΗ ΠΑΡΟΥΣΙΑΣΗ ΠΡΟΤΥΠΩΝ · 2020-03-16 · [Έγγρ] Αγγλ.τίτλος Artificial climbing structures - Part 2: Safety requirements and test methods](https://static.fdocument.org/doc/165x107/5e955c97763bc418a45dd833/-2020-03-16-.jpg)
Antibiotics Keep Climbing
1
INDUSTRY & BUSINESS Theae Successes Against Disease 1945-56 decline in death rates per 100,000 population for diseases against which antibiotics are effective a Β Ο uina Β Down 33% * «— v>> w Ο es J» SE Down w o r -a ο *Λ il! «ι= Down 71% Down 71% Dawn 78f 0 Down 85% Source: U S- Public Health Service Down 89% Down 92% , . » Premise a Hefty Sales Growth for Antibiotics Forecast of Domestic Human Dosage—Form Antibiotic Sales at Manufacturers Level /Aillions of Dollars $444 1958.. . 1960 1962 Source: G. B. Stone, "A Long Range Economic Outlook for the Ethical Drug Industry." 1964 1965 Antibiotics Keep Climbing Sales hit $380 million in 1958 for human uses alone, will lump another 15% by 1965 ^ALXTIBIOTICS SALES hit a new high in 1958. Total value of antibiotics sold by the pharmaceutical industry for human medicines is estimated at $380 million, according to John E. McKeen, president of Chas. Pfizer. Another $70 million worth went into feed supple- ments, veterinary drugs, pesticides, pre- servatives, and other miscellaneous products, McKeen told the Midwest Forum of the Investment Analysts So- ciety of Chicago. McKeen also says mat anuuiolics sales will continue to rise, thanks to a growing population and research dis- coveries. By 1965, he says, sales at the manufacturers' level should climb another 15'/* for human use alone—up to $440 million. And more antibiotics will be used in agriculture and industry. Research, says McKeen, is the key to the drug industry's growth. In 1959. pharmaceutical firms will spend something like $190 million for re- search, or 7 cents out of every sales dol- lar (compared to the general industry average tu 1 eeni ;. -Moreover, piiarrna- ceutical development abroad will spur the drug industry to greater achieve- ments. He cites the forthcoming (in 1961) International Public Health and Medical Research Year. The Medical Year, McKeen notes, will focus world- wide attention on disease, medical tech- niques, and research. Post-war antibiotics research and use has caused a major drop in the death rate for eight infectious diseases, says McKeen. Average drop is 58V<. The tuberculosis death rate has been slashed the most—by nearly 80'ί be- tween 1945 and 1956. In the same period, deaths from pneumonia, men- ingococcal infections, mastmd and ear infections, syphilis, whooping cough, scarlet fever, and diphtheria also showed sharp declines, says McKeen. Equally significant decreases in the hav occurred. JAN. 2 6, 1 9 5 9 C&EN 27
Transcript of Antibiotics Keep Climbing
INDUSTRY & BUSINESS
Theae Successes A g a i n s t Disease 1945-56 decline in death rates per 100 ,000 population for diseases against which antibiotics are effective
a Β Ο uina
Β
Down 33%
* « — v>>
w Ο es J» SE
Down
w o r
- a ο
* Λ il!
«ι=
Down 7 1 %
Down 7 1 % Dawn
78f0 Down 85%
Source: U S- Public Health Service
Down 89% Down
92%
, . » Premise a Hefty Sales G r o w t h for Antibiotics Forecast of Domestic Human Dosage—Form Antibiotic Sales at Manufacturers Level
/Aillions of Dollars
$444
1958.. . 1960 1962 Source: G. B. Stone, "A Long Range Economic Outlook for the Ethical Drug Industry."
1964 1965
Antibiotics Keep Climbing Sales hit $380 million in 1958 for human uses alone, wil l lump another 15% by 1965
^ALXTIBIOTICS SALES hit a new high in 1958. Total value of antibiotics sold by the pharmaceutical industry for human medicines is estimated at $380 million, according to John E. McKeen, president of Chas . Pfizer. Another $70 million worth went into feed supplements, veterinary drugs, pesticides, preservatives, and other miscellaneous products, McKeen told the Midwest Forum of the Investment Analysts Society of Chicago.
McKeen also says mat anuuiolics sales will continue to rise, thanks to a
growing population and research discoveries. By 1965, he says, sales at the manufacturers' level should climb another 15'/* for human use alone—up to $440 million. And more antibiotics will be used in agriculture and industry.
Research, says McKeen, is the key to the drug industry's growth. In 1959. pharmaceutical firms will spend something like $190 million for research, or 7 cents out of every sales dollar (compared to the general industry average tu 1 eeni ;. -Moreover, piiarrna-ceutical development abroad will spur
the drug industry to greater achievements. He cites the forthcoming (in 1961) International Public Health and Medical Research Year. The Medical Year, McKeen notes, will focus worldwide attention on disease, medical techniques, and research.
Post-war antibiotics research and use has caused a major drop in the death rate for eight infectious diseases, says McKeen. Average drop is 58V<. The tuberculosis death rate has been slashed the most—by nearly 80'ί between 1945 and 1956. In the same period, deaths from pneumonia, meningococcal infections, mastmd and ear infections, syphilis, whooping cough, scarlet fever, and diphtheria also showed sharp declines, says McKeen. Equally significant decreases in the
hav occurred.
J A N . 2 6, 1 9 5 9 C & E N 2 7
